Basisstatistiken
| LEI | 5299006YIA3L0MBW8358 |
| CIK | 1410098 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CorMedix Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 14, 2026 |
Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Parsippany, NJ – May 14, 2026 – CorMedix Ther |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 14, 2026 |
CORMEDIX INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 CORMEDIX INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of May 12, 2026 (the “Effective Date”), by and between CorMedix Inc., a Delaware corporation (the “Company”), and Beth Zelnick Kaufman (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together th |
|
| May 14, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3 |
|
| May 14, 2026 |
CORMEDIX INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 CORMEDIX INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of May 12, 2026 (the “Effective Date”), by and between CorMedix Inc., a Delaware corporation (the “Company”), and Elizabeth Hurlburt (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they |
|
| May 14, 2026 |
CORMEDIX INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 CORMEDIX INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of May 12, 2026 (the “Effective Date”), by and between CorMedix Inc., a Delaware corporation (the “Company”), and Susan Blum (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are ref |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON, DC 20549 FORM 10-K 6 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 27, 2026 |
Exhibit 99.1 CORMEDIX Therapeutics AnnounceS POSITIVE Topline Results from PHASE III respect TriaL assessing Rezzayo® for the PROPHYLAXIS of invasive fungal diseases in ALLOGENEIC Haematopoietic Stem Cell Transplantation PATIENTS – The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 6, 2026 |
Exhibit 99.1 NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Corporate Presentation March 2026 CorMedix Therapeutics NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 2 This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27 A of the Securiti |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 5, 2026 |
Subsidiaries of the Registrant* Exhibit 21.1 Subsidiaries of the Registrant* Subsidiary Jurisdiction of Incorporation Melinta Therapeutics, LLC Delaware Melinta Subsidiary Corp. Delaware Rempex Pharmaceuticals, Inc. Delaware Targanta Therapeutics Corporation Delaware CEM-102 Pharmaceuticals, Inc. Delaware Cempra Pharmaceuticals, Inc. Delaware * Inclusion on the list above is not an admission that any of the above entities, indiv |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 5, 2026 |
Exhibit 19.1 TITLE: Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities Document No.: LEG-POL-001.3 Effective Date: January 30, 2026 Page: 1 of 16 POLICY SUMMARY Functional Owner Legal Why do we have this policy? This Policy is designed to promote compliance with applicable securities laws by the Company and Company Personnel, and to preserve the Compan |
|
| March 5, 2026 |
CorMedix Inc. Executive Employment Agreement Exhibit 10.19 CorMedix Inc. Executive Employment Agreement This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of March 16, 2022 (the “Effective Date”), by and between CorMedix Inc., a Delaware corporation (the “Company”), and Joseph Todisco (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties”. Terms In |
|
| March 5, 2026 |
Exhibit 99.1 CorMedix Inc. Reports FOURTH Quarter AND FULL YEAR 2025 Financial Results and provides business update ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Parsippany, NJ – March 5, 2026 – CorMedix I |
|
| March 5, 2026 |
DESCRIPTION OF CAPITAL STOCK OF CORMEDIX INC. Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK OF CORMEDIX INC. Common Stock The following is a summary of certain provisions of the capital stock of CorMedix Inc. (referred to herein as “we,” “us,” “our” and “Company”). Such summary does not purport to be complete. You should refer to our Amended and Restated Certificate of Incorporation, as amended, and our Amended and Restated Bylaws and each Certifi |
|
| January 8, 2026 |
CorMedix Therapeutics announces leadership and board updates Exhibit 99.2 CorMedix Therapeutics announces leadership and board updates Berkeley Heights, NJ – January 8, 2026 – CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix C |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2026 CORMEDIX INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 8, 2026 |
Exhibit 99.1 CorMedix THERAPEUTICS announces preliminary Fourth quarter and full year 2025 results and provides business updates ‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 million ‒ ‒ Unaudited Cash and Short-term Investments of Approximately $1 |
|
| November 13, 2025 |
As filed with the Securities and Exchange Commission on November 13, 2025 As filed with the Securities and Exchange Commission on November 13, 2025 Registration Statement No. |
|
| November 13, 2025 |
CALCULATION OF FILING FEE TABLES CorMedix Inc. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 CorMedix Inc. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 per share (1) Other 7,672,000 $ 10.72 $ 82,243,840.00 0.0001381 $ 11, |
|
| November 12, 2025 |
Exhibit 99.1 CorMedix Inc. Reports third Quarter 2025 Financial Results and UpdateS FY 2025 GUIDANCE ‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Easte |
|
| November 12, 2025 |
Amendment No. 2 to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan. Exhibit 10.5 AMENDMENT No. 2 TO THE CORMEDIX INC. AMENDED & RESTATED 2019 OMNIBUS STOCK INCENTIVE PLAN This Amendment No. 2 (this “Amendment”) to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan, as amended (the “Plan”), is made effective as of this 10th day of September 2025. WHEREAS, CorMedix Inc. (the “Company”) maintains the Plan; WHEREAS, pursuant to Section 16 of the |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| October 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| October 20, 2025 |
Exhibit 99.1 CorMedix Inc. announces preliminary THIRD quarter 2025 results and RAISES 2025 NET REVENUE GUIDANCE ‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒ ‒ Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million ‒ ‒ Raising FY 2025 Pro Forma Net Revenue Guidance to at least $375 million ‒ ‒ ~$30mm of operating synergy on a go-forward run-rate basis before year |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 20, 2025 CORMEDIX INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| October 7, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 CorMedix Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.001 pa |
|
| October 7, 2025 |
As filed with the Securities and Exchange Commission on October 7, 2025 As filed with the Securities and Exchange Commission on October 7, 2025 Registration Statement No. |
|
| October 7, 2025 |
CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 October 7, 2025 Division of Corporation Finance Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3561 Re: CorMedix Inc. (CIK: 0001410098) Form S-3ASR Filed on October 6, 2025 File No. 333-290721 Pursuant to Rule 477 under the Securities Act of 1933, as amended, CorMedix Inc. (the “Registrant”) hereby r |
|
| October 6, 2025 |
As filed with the Securities and Exchange Commission on September 30, 2025 As filed with the Securities and Exchange Commission on September 30, 2025 Registration Statement No. |
|
| October 6, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 CorMedix Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.001 pa |
|
| October 6, 2025 |
CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 October 3, 2025 Division of Corporation Finance Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3561 Re: CorMedix Inc. (CIK: 0001410098) Form S-3 Filed on September 30, 2025 File No. 333-290636 Pursuant to Rule 477 under the Securities Act of 1933, as amended, CorMedix Inc. (the “Registrant”) hereby r |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 29, 2025 CorMedix Inc. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation) (Comm |
|
| September 30, 2025 |
As filed with the Securities and Exchange Commission on September 30, 2025 As filed with the Securities and Exchange Commission on September 30, 2025 Registration Statement No. |
|
| September 30, 2025 |
MELINTA THERAPEUTICS, LLC 2024 Consolidated Financial Statements Exhibit 99.2 MELINTA THERAPEUTICS, LLC 2024 Consolidated Financial Statements EisnerAmper LLP 111 Wood Avenue South Iselin, NJ 08830-2700 T 732.243.7000 F 732.951.7400 www.eisneramper.com INDEPENDENT AUDITORS’ REPORT To the Board of Directors and Shareholders of Melinta Therapeutics, LLC Report on the Audit of the Financial Statements Opinion We have audited the financial statements of Melinta The |
|
| September 30, 2025 |
Exhibit 99.3 MELINTA THERAPEUTICS, LLC Q2 2025 Consolidated Financial Statements INDEX TO CONSOLIDATED FINANCIAL STATEMENTS MELINTA THERAPEUTICS, LLC Page Consolidated Balance Sheets 2 Consolidated Statements of Operations 3 Consolidated Statements of Changes in Shareholders’ Equity 4 Consolidated Statements of Cash Flows 5 Notes to Consolidated Financial Statements 6 1 MELINTA THERAPEUTICS, INC. |
|
| September 30, 2025 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On August 29, 2025 (the “Closing Date”), CorMedix Inc., a Delaware corporation (the “Company,” “CorMedix,” “we,” “our” and “us”) completed its previously announced merger with Melinta Therapeutics, LLC, a Delaware limited liability company (“Melinta”). Pursuant to that certain Agreement and Plan of Merger, dated August 7, 202 |
|
| September 30, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 CorMedix Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.001 pa |
|
| September 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 12, 2025 |
144 0001304773 XXXXXXXX LIVE 0001410098 CorMedix Inc. 001-34673 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 908-517-9500 DUNTON ALAN W Director Common Merrill Lynch 1800 K St NW Suite 800 Washington DC 20006 10000 130950.00 74648992 09/12/2025 NASDAQ Common 09/12/2025 Stock plan activity Issuer N 10000 09/12/2025 n/a Y 09/12/2025 Alan Dunton |
|
| September 12, 2025 |
144 0001774807 XXXXXXXX LIVE 0001410098 CorMedix Inc. 001-34673 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 908-517-9500 Todisco Joseph Officer Common Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006 50000 648569.00 74648992 09/12/2025 NASDAQ Common 09/12/2025 Stock Plan Activity Issuer N 50000 09/12/2025 n/a Y 09/12/2025 Joseph Todisco |
|
| September 9, 2025 |
144 0002004480 XXXXXXXX LIVE 0001410098 CorMedix Inc. 001-34673 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 908-517-9500 Zelnick Kaufman Beth Officer Common Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006 50000 673000.00 74648992 09/09/2025 NASDAQ Common 09/09/2025 Stock Plan Activity Issuer N 50000 09/09/2025 n/a Y 09/09/2025 Beth Zelnick Kaufman |
|
| September 9, 2025 |
144 0001735256 XXXXXXXX LIVE 0001410098 CorMedix Inc. 001-34673 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 908-517-9500 Hurlburt Elizabeth Officer Common Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006 53997 728959.00 74648992 09/09/2025 NASDAQ Common 09/09/2025 Stock Plan Activity Issuer N 53997 09/09/2025 n/a Y 09/09/2025 Elizabeth Hurlburt |
|
| September 3, 2025 |
144 0001811612 XXXXXXXX LIVE 0001410098 CorMedix Inc. 001-34673 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 908-517-9500 David Matthew T Former Officer Common Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006 300000 4350000.00 74648992 09/03/2025 NASDAQ Common 09/03/2025 Stock Plan Activity Issuer N 300000 09/03/2025 n/a Y 09/03/2025 Matthew David |
|
| September 2, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS IDENTIFIED HEREIN WITH “[***].” SCHEDULES AND EXHIBITS HAVE BEEN OMITTED PURSUANT TO ITEM 601(A)(5) OF REGULATION S-K. Execution Version CONTINGENT PAYMENT AGREEMENT This CONTINGENT PAYMENT AGREEMENT (this “Agreement”), d |
|
| September 2, 2025 |
Exhibit 99.1 CorMedix completes ACQUIsition of MELINTA THERAPEUTICS AND ANNOUNCES NEW LEADERSHIP TEAM - Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - - Revised guidance of pro forma 2025 combined revenues, now estimated to be in |
|
| September 2, 2025 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 31, 2025 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Dr. Matt David (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the foregoing premis |
|
| September 2, 2025 |
Exhibit 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 29, 2025, by and among CorMedix Inc., a Delaware corporation (the “Company”), Deerfield Private Design Fund IV, L.P. (“DPDF IV”), Deerfield Private Design Fund III, L.P. (“DPDF III” and, together with DPDF IV, the “Initial Holders”) and each other Holder (as defined bel |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 CorMedix Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34473 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 2, 2025 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 29, 2025 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Elizabeth Hurlburt (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the foregoing pr |
|
| September 2, 2025 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 28, 2025 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Susan Blum (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the fo |
|
| August 12, 2025 |
Exhibit 4.1 CORMEDIX INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August 12, 2025 4.00% Convertible Senior Notes due 2030 Table of Contents Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 21 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amount 21 Secti |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 CorMedix Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 CorMedix Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34473 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 7, 2025 |
Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of August 7, 2025, among CorMedix Inc., Coriander Bidco LLC, MELINTA THERAPEUTICS, LLC, AND Deerfield Private Design Fund IV, L.P., as the Members’ REPRESENTATIVE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFOR |
|
| August 7, 2025 |
Exhibit 99.5 August 6, 2025 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, New Jersey 07922 Re: Subscription for 4.00% Convertible Senior Notes due 2030 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (the “Company”), is offering the undersigned investor (the “Investor”), on behalf of itself and each account (if any) listed on Exhibit A hereto for whom the Investor has b |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 7, 2025 |
Exhibit 99.2 CorMedix TO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED SPECIALTY COMPANY WITH STRONG PRESENCE IN ACUTE CARE SETTINGS - Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - Transaction expected to be near-term accre |
|
| August 7, 2025 |
Exhibit 4.1 CORMEDIX INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August [12], 2025 4.00% Convertible Senior Notes due 2030 Table of Contents Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 21 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amount 21 Sec |
|
| August 7, 2025 |
Selected Melinta Therapeutics, LLC Financial Information1 Exhibit 99.3 Selected Melinta Therapeutics, LLC Financial Information1 ($ in millions) 2024A Q1 2025A Q2 2025A Net Product Revenue $ 106 $ 26 $ 29 Contract Revenue 11 License and Other Revenue 2 Other Revenue2 $ 14 $ 4 $ 4 Total Revenue $ 120 $ 30 $ 33 Cost of Goods Sold $ (27 ) $ (7 ) $ (8 ) Gross Profit $ 93 $ 23 $ 26 % Margin 77 % 77 % 77 % Research & Development $ (15 ) $ (4 ) $ (5 ) Selling, |
|
| August 7, 2025 |
Exhibit 99.1 CorMedix Inc. Reports second Quarter 2025 Financial Results and Provides Business Update ‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Berkeley Heights, NJ – August 7, 2025 – CorMedix Inc. (Nasdaq: CRMD) today announced fin |
|
| August 7, 2025 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF SERIES E CONVERTIBLE PREFERRED STOCK OF CORMEDIX INC. Pursuant to Section 242 of the Delaware General Corporation Law I, Joseph Todisco, Chief Executive Officer of CorMedix Inc. (the “Corporation”) a corporation organized and existing under the laws of the State of Delaware, DO HEREBY CERTIFY: A. Pursuant to its Certificate of In |
|
| August 7, 2025 |
Exhibit 99.4 Acquisition of Melinta Therapeutics August 7, 2025 Disclaimer This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27 A of the Securities Act, and Section 21 E of the Exchange, as amended (the “Exchange Act”), that are subject to risks and uncertainties . Forward - looking statements are often id |
|
| June 30, 2025 |
Underwriting Agreement dated June 26, 2025 Exhibit 1.1 Execution Version CorMedix Inc. 6,604,507 Shares of Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York June 26, 2025 RBC Capital Markets, LLC As Representative of the several Underwriters listed on Schedule I hereto c/o RBC Capital Markets, LLC 200 Vesey Street New York, New York 10281-8098 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (th |
|
| June 30, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 30, 2025 |
CorMedix Inc. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 CorMedix Inc. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ – June 27, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its co |
|
| June 30, 2025 |
$85,000,000 CorMedix Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279277 Prospectus Supplement (To prospectus dated May 22, 2024) $85,000,000 CorMedix Inc. Common Stock We are offering 6,604,507 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “CRMD.” On June 25, 2025, the last reported sale price of our common stock on the Nasdaq Global Market was $14.97 per |
|
| June 30, 2025 |
CorMedix Inc. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 CorMedix Inc. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ – June 26, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it intends to offer and sell $85.0 million of shares of its common stock in an underwritten pub |
|
| June 26, 2025 |
Subject to Completion, dated June 26, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-279277 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| June 25, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commis |
|
| June 23, 2025 |
CorMedix Inc. announces customer IMPLEMENTATION Exhibit 99.1 CorMedix Inc. announces customer IMPLEMENTATION Berkeley Heights, NJ – June 23, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 6, 2025 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – May 6, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threate |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON, DC 20549 FORM 10-K 6 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 22, 2025 |
Letter from Marcum dated April 22, 2025 Exhibit 16.1 April 22, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by CorMedix Inc. under Item 4.01 of its Form 8-K dated April 22, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of CorMedix Inc. contained therein. Very tr |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 8, 2025 |
Exhibit 99.1 CorMedix Inc. announces preliminary FIRST quarter 2025 results and RAISES H1 2025 NET SALES GUIDANCE ‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ Berkeley Heights, NJ – April 8, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on develo |
|
| March 25, 2025 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Berkeley Heights, NJ – March 25, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical comp |
|
| March 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 25, 2025 |
Exhibit 10.16 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of December 12, 2023 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Beth Zelnick Kaufman (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the foregoi |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 25, 2025 |
Insider Trading Policies and Procedures Exhibit 19.1 TITLE: INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Document No.: LEG-POL-001.1 Effective Date: October 30, 2024 Page: 1 of 12 1.0 PURPOSE 1.1 The purpose of this policy is to guide everyone who works for or provides services to CorMedix Inc. (the “Company”) concerning trading in the Company’s securities and in securities of publicly |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Advisors, LLC Aperio Group, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the secur |
|
| January 7, 2025 |
Exhibit 99.1 CorMedix Inc. announces preliminary Fourth quarter 2024 results and provides business update ‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ Berkeley Heights, NJ – January 7, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commerci |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 7, 2025 CORMEDIX INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
|
| November 14, 2024 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CorMedix Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 21900C308 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| October 30, 2024 |
Exhibit 99.1 CorMedix Inc. Reports THIRD Quarter AND NINE MONTH 2024 Financial Results and Provides Business Update ‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Berkeley Heights, NJ – October 30, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company foc |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| August 14, 2024 |
Exhibit 99.1 CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – August 14, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announce |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| May 20, 2024 |
CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 May 20, 2024 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Division of Corporation Finance, Office of Life Sciences Re: CorMedix Inc. Registration Statement on Form S-3 Filed May 9, 2024 File No. 333-279277 Ladies and Gentlemen: Pur |
|
| May 15, 2024 |
United States securities and exchange commission logo May 15, 2024 Joseph Todisco Chief Executive Officer CorMedix Inc. |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) CorMedix Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration Statement No. |
|
| May 9, 2024 |
Sales Agreement with Leerink Partners LLC dated May 9, 2024 Exhibit 1.2 CORMEDIX INC. Common Stock (par value $0.001 per share) SALES AGREEMENT May 9, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (the “Company”) and Leerink Partners LLC (the “Agent”, together with the Company, each a “Party” and collectively, the “Parties”) and hereby agree as follows: |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 9, 2024 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – May 9, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results |
|
| March 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 12, 2024 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – March 12, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases |
|
| March 12, 2024 |
Board Policy on Recouping Incentive Compensation Exhibit 97.1 Final as Approved Compensation Recoupment Policy of CorMedix Inc. Adopted to go into effect on December 1, 2023, with retroactive effectiveness to the Effective Date Article A. Purpose And General Terms Section A-1. Purpose. CorMedix Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to: (a) implement a mandatory clawback policy in the event of a Rest |
|
| March 12, 2024 |
Separation Agreement, effective December 14, 2023, between CorMedix Inc. and Phoebe Mounts. Exhibit 10.17 Separation Agreement and Release This Separation Agreement and Release (the “Agreement”), effective December 14, 2023 (“Delivery Date”), sets forth the terms of the separation of Phoebe Mounts (“you” or “your”) from employment with CorMedix Inc. (the “Company”). If you understand and agree with these terms, please sign in the space provided below. If you and the Company sign below, t |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| February 14, 2024 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC Passive Investment SC 13G/A 1 sayw2402144613ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CorMedix Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 21900C308 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2024 |
CRMD / CorMedix Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: CorMedix Inc Title of Class of Securities: Common Stock CUSIP Number: 21900C308 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1 |
|
| January 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 30, 2024 |
CORMEDIX INC. announces commercial AND REiMBURSEMENT updates Exhibit 99.1 CORMEDIX INC. announces commercial AND REiMBURSEMENT updates Berkeley Heights, NJ – January 30, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced updates related to its business and anticipated launch of DefenCath®. |
|
| January 29, 2024 |
CRMD / CorMedix Inc. / BlackRock Inc. Passive Investment SC 13G 1 us21900c3088012924.txt us21900c3088012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) CORMEDIX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 21900C308 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
|
| November 16, 2023 |
Exhibit 99.1 CORMEDIX INC. ANNOUNCES FDA APProval of Defencath® To reduce the incidence of catheter-related bloodstream infections in adult hemodialysis patients – First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting Berkeley Heights, NJ – November 15, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biop |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| November 14, 2023 |
Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – November 14, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening disea |
|
| October 30, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON, DC 20549 FORM 10-K 6 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 8, 2023 |
Exhibit 99.1 CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2023 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – August 8, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| June 30, 2023 |
Form of Pre-Funded Warrant issued June 28, 2023 Exhibit 4.1 CORMEDIX INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. Number of Shares: (subject to adjustment) Original Issue Date: CorMedix Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, , or its permitted assigns (the “Holder”), is entitled to purchase fro |
|
| June 30, 2023 |
Exhibit 99.2 CORMEDIX INC. ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Berkeley Heights, NJ – June 28, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the pricing of its previously |
|
| June 30, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258756 Prospectus Supplement (To prospectus dated August 20, 2021) CorMedix Inc. 7,500,000 Shares of Common Stock and Pre-Funded Warrants to Purchase Up to 2,500,625 Shares of Common Stock 2,500,625 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 7,500,000 shares of our common stock and, in lieu of common stock to cert |
|
| June 30, 2023 |
CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Exhibit 99.1 CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Berkeley Heights, NJ – June 28, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that it intends to offer and sell shares of |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 30, 2023 |
Underwriting Agreement dated June 28, 2023 Exhibit 1.1 CorMedix Inc. 7,500,000 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,500,625 Shares of Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York June 28, 2023 RBC Capital Markets, LLC Truist Securities, Inc. As Representatives of the several Underwriters listed on Schedule I hereto c/o RBC Capital Markets, LLC 200 Vesey Street New York, New Y |
|
| June 28, 2023 |
Subject to Completion, dated June 28, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-258756 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| June 21, 2023 |
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH Exhibit 99.1 CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ – June 21, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the resubmission of the New Drug Ap |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 16, 2023 |
CorMedix Inc. ANNOUNCES RESUBMISSION Of New drug application for defencath Exhibit 99.1 CorMedix Inc. ANNOUNCES RESUBMISSION Of New drug application for defencath Berkeley Heights, NJ – May 16, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the New Drug Application for DefenCath was resubmitted |
|
| May 15, 2023 |
Exhibit 10.1 CORMEDIX INC. INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [●], between CorMedix Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are provided with adequate protec |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 15, 2023 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – May 15, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 26, 2023 |
CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES Berkeley Heights, NJ – April 26, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that following its Type A meeting with the FDA, the Comp |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commi |
|
| April 17, 2023 |
CORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS Exhibit 99.1 CORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS Berkeley Heights, NJ – April 17, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMe |
|
| March 30, 2023 |
Exhbit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – March 30, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 30, 2023 |
Exhibit 10.1 * Information in this exhibit marked [***] has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated as private or confidential. LICENSE AND ASSIGNMENT AGREEMENT between ND PARTNERS LLC and CORMEDIX, INC. LICENSE AND ASSIGNMENT AGREEMENT This License and Assignment Agreement (hereinafter referred to as this “Agreement”), ef |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 3, 2023 |
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Berkeley Heights, NJ – March 2, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced updates related to the FDA compliance remediation activities at its prim |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| February 14, 2023 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC - SC 13G/A Passive Investment SC 13G/A 1 brhc10047775sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CorMedix Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 21900C308 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| November 10, 2022 |
Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – November 10, 2022 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and disea |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| October 26, 2022 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CorMedix Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock(1) 457(c) and 457(h |
|
| October 26, 2022 |
Amended and Restated 2019 Omnibus Stock Incentive Plan Exhibit 99.1 Amended and Restated CORMEDIX INC. 2019 omnibus stock INCENTIVE PLAN Approved by the Board August 23, 2022 and by the Stockholders on October 13, 2022 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel; to provide additional incentives to Employees, Directors and Consultants to contribute to the successful performance of the Compa |
|
| October 26, 2022 |
As filed with the Securities and Exchange Commission on October 26, 2022 As filed with the Securities and Exchange Commission on October 26, 2022 Registration Statement No. |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 21, 2022 |
Letter from Friedman LLP to the Securities and Exchange Commission dated October 21, 2022. Exhibit 16.1 October 21, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: CorMedix Inc. Commission File Number 001-34673 Commissioners: We have read the statements made by CorMedix Inc. under Item 4.01 of its Form 8-K dated October 21, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| August 11, 2022 |
Exhibit 99.1 CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ ? August 11, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammat |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 9, 2022 |
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Berkeley Heights, NJ ? August 8, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates related to the FDA review of the DefenCath New Drug Application (NDA |
|
| August 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| July 8, 2022 |
CRMD / CorMedix Inc. / BlackRock Inc. Passive Investment us21900c3088070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) CORMEDIX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 21900C308 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| May 12, 2022 |
CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES Exhibit 99.2 CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES Berkeley Heights, NJ ? May 12, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its leadership team and changes regarding its internat |
|
| May 12, 2022 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? May 12, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today |
|
| March 29, 2022 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? March 29, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammato |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 28, 2022 |
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Exhibit 99.1 CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ ? March 28, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the resubmission of the New Drug Applic |
|
| March 28, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 21, 2022 |
Executive Employment Agreement, dated March 16, 2022, between CorMedix Inc. and Joseph Todisco. Exhibit 10.1 CORMEDIX INC. EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of March 16, 2022 (the ?Effective Date?), by and between CorMedix Inc., a Delaware corporation (the ?Company?), and Joseph Todisco (?Executive?). Each of the Company and Executive is referred to herein as a ?Party? and together they are referred to as the ?Parties.? TERMS In |
|
| March 21, 2022 |
Exhibit 99.1 CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry Berkeley Heights, NJ ? March 17, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commerc |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2022 CORMEDIX INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| February 28, 2022 |
CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Exhibit 99.1 CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ ? February 28, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted the New Drug Application (NDA) for |
|
| February 28, 2022 |
Exhibit 99.2 CORMEDIX DefenCath TM : A potentially new standard - of - care in the prevention of catheter related blood stream infections CORMEDIX This presentation contains certain statements that constitute forward - looking statements within the meaning of the federal securities laws . Statements that are not historical facts, including statements about our beliefs and expectations, are forward |
|
| February 28, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 14, 2022 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CorMedix Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 21900C308 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 3, 2022 |
CRMD / CorMedix Inc. / BlackRock Inc. Passive Investment us21900c3088020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CORMEDIX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 21900C308 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 23, 2021 |
Exhibit 10.2 [CorMedix Letterhead] Personal and Confidential [DATE] [Employee Name] Subject: CorMedix Inc. Special Performance Bonus Dear [First Name]: On behalf of CorMedix Inc. (the ?Company?), I am pleased to inform you that you will be eligible to receive a special cash performance bonus (?Bonus?) under the CorMedix Inc. Executive Bonus Plan (?Plan?). The Bonus will be payable based on the ach |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 CORMEDIX INC. |
|
| December 23, 2021 |
Exhibit 10.1 CORMEDIX INC. EXECUTIVE BONUS PLAN I. Purpose. The purpose of the CorMedix Inc. Executive Bonus Plan (the ?Plan?) is to provide a means whereby CorMedix Inc. (the ?Company?) may provide incentive compensation to its eligible employees to serve as an incentive for employee performance and retention. The Plan is effective as of December 20, 2021. II. Definitions. Whenever used in this P |
|
| December 13, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| November 9, 2021 |
Exhibit 10.2 Separation Agreement and Release This Separation Agreement and Release (the ?Agreement?) sets forth the terms of the separation of John L. Armstrong, Jr. (?you? or ?your?) from employment with CorMedix Inc. (the ?Company?). If you understand and agree with these terms, please sign in the space provided below. If you and the Company sign below, this will be a legally binding document r |
|
| November 9, 2021 |
Exhibit 10.1 Separation Agreement and Release This Separation Agreement and Release (the ?Agreement?) sets forth the terms of your separation from employment with CorMedix Inc. (the ?Company?). If you understand and agree with these terms, please sign in the space provided below. If you and the Company sign below, this will be a legally binding document representing the entire agreement between yo |
|
| November 9, 2021 |
Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? November 9, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, t |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 29, 2021 |
Exhibit 10.1 October 26, 2021 Matthew David, M.D. Re: Interim Chief Executive Officer Letter Agreement Dear Matt: As we have discussed, you will serve as the interim Chief Executive Officer of Cormedix Inc. (?Interim CEO?), effective as of October 4, 2021, until such time as Cormedix appoints a new Chief Executive Officer. You understand and agree that you will also continue to serve as CorMedix?s |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 29, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| September 7, 2021 |
CORMEDIX INC. ANNOUNCES REGULATORY UPDATE Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY UPDATE Berkeley Heights, NJ ? September 7, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update with respect to its resubmission timeline for the DefenCath New Drug Application (? |
|
| September 7, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| August 18, 2021 |
United States securities and exchange commission logo August 18, 2021 Khoso Baluch Chief Executive Officer CorMedix Inc. |
|
| August 18, 2021 |
CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 August 18, 2021 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento, Attorney-Advisor Re: CorMedix Inc. Registration Statement on Form S-3 Filed August 12, 2021 File No. 333-258756 Ladies and Gentlemen: Pursuant to Rule 46 |
|
| August 12, 2021 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To prospectus dated November 25, 2020) Registration No. |
|
| August 12, 2021 |
Exhibit 1.1 CORMEDIX INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement August 12, 2021 Truist Securities, Inc. 3333 Peachtree Road NE, 11th Floor Atlanta, Georgia 30326 JMP Securities LLC 600 Montgomery Street, Suite 1100 San Francisco, California 94111 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (the ?Company?), Truist Securities, Inc. (?Truist?) an |
|
| August 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 12, 2021 |
Exhibit 99.1 CORMEDIX INC. REPORTS Second QUARTER and six month 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? August 12, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammat |
|
| August 12, 2021 |
Exhibit 10.1 IN ACCORDANCE WITH ITEM 601(b)(10) of REGULATION S-K, CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT 10.10 BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH INFORMATION IS IDENTIFIED BY [***] EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of April 29, 2021 by an |
|
| August 12, 2021 |
As filed with the Securities and Exchange Commission on August 12, 2021 As filed with the Securities and Exchange Commission on August 12, 2021 Registration Statement No. |
|
| May 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 14, 2021 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? May 13, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today |
|
| May 14, 2021 |
Exhibit 99.1 CorMedix Inc. Announces Appointment of Chief Commercial Officer Thomas Nusbickel to join CorMedix as Chief Commercial Officer; Brings significant experience in renal product launches and commercialization Berkeley Heights, NJ ? May 13, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| April 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 15, 2021 |
CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA Exhibit 99.1 CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA Berkeley Heights, NJ — April 14, 2021 — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has met with the US Food and Drug Administration (FDA) to d |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 30, 2021 |
Exhibit 10.10 IN ACCORDANCE WITH ITEM 601(b)(10) of REGULATION S-K, CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT 10.10 BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of May 11, 2020 by and between CorMedix Inc., a Delaware corpo |
|
| March 30, 2021 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – March 30, 2021 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammato |
|
| March 30, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 12, 2021 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of March 10, 2021 (the ?Effective Date?) by and between CorMedix Inc., a Delaware corporation (the ?Company?), and Elizabeth Masson-Hurlburt (?Executive?). Each of the Company and Executive is referred to herein as a ?Party? and together they are referred to as the ?Parties.? TERMS In cons |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 1, 2021 |
CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION Exhibit 99.1 CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION Berkeley Heights, NJ — March 1, 2021 — CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration (FDA) c |
|
| March 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| February 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) CorMedix Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21900C308 (CUSIP Number) Elliott Investment Management, L.P. Phillips Point, East Tower 777 South Flagler Drive, Suite 1000 West Palm Beach, FL 33401 with a copy to |
|
| February 5, 2021 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (to Prospectus dated November 25, 2020) Registration No. |
|
| February 2, 2021 |
begin 644 8ACertCRMD.pdf M)5!$1BTQ+C8-)>+CS],-"C0V(# @;V)J#3P\+TQI;[email protected]$O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H,(AFG@-D30"1+(IA=!"*9? 0(, "YK%G4-"F5N9'-T/55ORN- $Q:EPTYG*:B&V,*O#S6=A8.HT@(@R2@($& #$=1%2 M#0IE;F1S=')E86T-96YD;V)J#30W(# @;V)J#3P\+TQA;F6]U="]/;F5#;VQU;6XO4&%G97,@-#0@,"!2+U-T%LP+C @,"XP(#8Q,BXP(#'1'4W1A=&4\/"]'4S @-S@@,"!2/CXO M1F]N=#P\+U14," X," P(%(O5%0Q(#@R(# |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 20-5894890 (State of other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 300 Conn |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-34673 CORMEDIX INC. NYSE American LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 300 Connell Drive, Sui |
|
| January 29, 2021 |
us21900c3088012921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) CORMEDIX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 21900C308 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| January 21, 2021 |
CORMEDIX INC. To begin trading on the Nasdaq Stock exchange Exhibit 99.1 CORMEDIX INC. To begin trading on the Nasdaq Stock exchange Berkeley Heights, NJ – January 21, 2021 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved for listing on the Nasdaq Global Market. T |
|
| December 18, 2020 |
Submission of Matters to a Vote of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
